/
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
11.40% operating margin is respectable but not wide. ROIC at 9.24%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 60.1% YoY with margins expanding 22.2pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$754M
▲ +60.1% YoY
Net Income (TTM)
$73M
▲ +236.6% YoY
Op. Margin
12.36%
▲ +22.2pp YoY
ROIC
10.76%
▲ +17.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$164M
▲ +436.8% YoY
Op. Cash Flow (TTM)
$166M
▲ +437.1% YoY
Net Debt
-$459M
Net Cash Position
Cash & Equiv.
$468M
3Y CAGR: +45.5%
Continue Research